TY - JOUR
T1 - Cutaneous manifestations of nontargeted and targeted chemotherapies
AU - Shi, Veronica J.
AU - Levy, Lauren L.
AU - Choi, Jennifer N.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Care of the oncologic patient requires an integral understanding of the adverse reactions of chemotherapy. With the advent of targeted agents and immunomodulating therapies, reactions to these newer treatments are of clinical interest. Cutaneous side effects of chemotherapeutic agents, including toxic erythema and mucositis, are common and may require cessation of treatment if associated with discomfort, superinfection, or negative impact on quality of life. This article reviews the cutaneous adverse reactions and treatment options of both conventional cytotoxic chemotherapeutic agents and newer targeted, multikinase inhibitors and immunomodulating therapies. An understanding of possible cutaneous reactions by all providers involved in the care of the oncologic patient is critical for prompt recognition, allowing for appropriate treatment and referral to dermatologists when necessary.
AB - Care of the oncologic patient requires an integral understanding of the adverse reactions of chemotherapy. With the advent of targeted agents and immunomodulating therapies, reactions to these newer treatments are of clinical interest. Cutaneous side effects of chemotherapeutic agents, including toxic erythema and mucositis, are common and may require cessation of treatment if associated with discomfort, superinfection, or negative impact on quality of life. This article reviews the cutaneous adverse reactions and treatment options of both conventional cytotoxic chemotherapeutic agents and newer targeted, multikinase inhibitors and immunomodulating therapies. An understanding of possible cutaneous reactions by all providers involved in the care of the oncologic patient is critical for prompt recognition, allowing for appropriate treatment and referral to dermatologists when necessary.
KW - Cutaneous adverse reactions
KW - Cytotoxic chemotherapy
KW - Immunotherapy
KW - Multikinase inhibitors
KW - Targeted chemotherapy
KW - Toxic erythema
UR - http://www.scopus.com/inward/record.url?scp=84963556458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963556458&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2016.02.018
DO - 10.1053/j.seminoncol.2016.02.018
M3 - Review article
C2 - 27178698
AN - SCOPUS:84963556458
SN - 0093-7754
VL - 43
SP - 419
EP - 425
JO - Seminars in Oncology
JF - Seminars in Oncology
IS - 3
ER -